Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project

K. M. Kerr*, U. Dafni, K. Schulze, E. Thunnissen, L. Bubendorf, H. Hager, S. Finn, W. Biernat, L. Vliegen, J. H. Losa, A. Marchetti, R. Cheney, A. Warth, E. -J. Speel, F. Blackhall, K. Monkhorst, E. Jantus Lewintre, V. Tischler, C. Clark, J. Bertran-AlamilloP. Meldgaard, K. Gately, A. Wrona, P. Vandenberghe, E. Felip, G. De Luca, S. Savic, T. Muley, E. F. Smit, A. -M. C. Dingemans, L. Priest, P. Baas, C. Camps, W. Weder, V. Polydoropoulou, T. R. Geiger, R. Kammler, T. Sumiyoshi, M. A. Molina, D. S. Shames, R. A. Stahel, S. Peters, Etop Lungscape Consortium

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)200-208
Number of pages9
JournalAnnals of Oncology
Volume29
Issue number1
DOIs
Publication statusPublished - 1 Jan 2018

Keywords

  • non-small-cell lung cancer
  • multiplex mutation analysis
  • EGFR
  • KRAS
  • PIK3CA
  • prognosis molecular staging
  • CELL LUNG-CANCER
  • TYROSINE KINASE INHIBITORS
  • PREDICT SURVIVAL
  • KRAS MUTATIONS
  • ADENOCARCINOMA
  • OVEREXPRESSION
  • HETEROGENEITY
  • AMPLIFICATION
  • VALIDATION

Cite this